• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Guideline of guidelines: non-muscle-invasive bladder cancer.指南之指南：非肌层浸润性膀胱癌
BJU Int. 2017 Mar;119(3):371-380. doi: 10.1111/bju.13760. Epub 2017 Jan 24.
2
Variability in adherence to guidelines based management of nonmuscle invasive bladder cancer among Society of Urologic Oncology (SUO) members.基于美国泌尿外科学会（SUO）成员的非肌肉浸润性膀胱癌指南管理的依从性存在差异。
Urol Oncol. 2020 Oct;38(10):796.e1-796.e6. doi: 10.1016/j.urolonc.2020.04.026. Epub 2020 May 17.
3
EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016.EAU 指南：非肌层浸润性膀胱尿路上皮癌：2016 年更新版。
Eur Urol. 2017 Mar;71(3):447-461. doi: 10.1016/j.eururo.2016.05.041. Epub 2016 Jun 17.
4
European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ) - 2019 Update.欧洲泌尿外科学会非肌肉浸润性膀胱癌（TaT1 和原位癌）指南 - 2019 年更新版。
Eur Urol. 2019 Nov;76(5):639-657. doi: 10.1016/j.eururo.2019.08.016. Epub 2019 Aug 20.
5
Discrepancy Between European Association of Urology Guidelines and Daily Practice in the Management of Non-muscle-invasive Bladder Cancer: Results of a European Survey.欧洲泌尿外科学会指南与非肌肉浸润性膀胱癌管理日常实践之间的差异：一项欧洲调查的结果。
Eur Urol Focus. 2019 Jul;5(4):681-688. doi: 10.1016/j.euf.2017.09.002. Epub 2017 Oct 23.
6
Current clinical practice gaps in the treatment of intermediate- and high-risk non-muscle-invasive bladder cancer (NMIBC) with emphasis on the use of bacillus Calmette-Guérin (BCG): results of an international individual patient data survey (IPDS).当前治疗中高危非肌肉浸润性膀胱癌（NMIBC）的临床实践差距，重点是卡介苗（BCG）的使用：国际个体患者数据调查（IPDS）的结果。
BJU Int. 2013 Oct;112(6):742-50. doi: 10.1111/bju.12012. Epub 2013 Mar 1.
7
Update on the guideline of guidelines: non-muscle-invasive bladder cancer.指南更新：非肌肉浸润性膀胱癌。
BJU Int. 2020 Feb;125(2):197-205. doi: 10.1111/bju.14915. Epub 2019 Nov 1.
8
European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (Ta, T1, and Carcinoma in Situ).欧洲泌尿外科学会非肌层浸润性膀胱癌（Ta、T1和原位癌）指南
Eur Urol. 2022 Jan;81(1):75-94. doi: 10.1016/j.eururo.2021.08.010. Epub 2021 Sep 10.
9
Management of non-muscle-invasive bladder cancer: quality of clinical practice guidelines and variations in recommendations.非肌肉浸润性膀胱癌的治疗管理：临床实践指南的质量和推荐意见的差异。
BMC Cancer. 2019 Nov 6;19(1):1054. doi: 10.1186/s12885-019-6304-y.
10
European Association of Urology (EAU) Prognostic Factor Risk Groups for Non-muscle-invasive Bladder Cancer (NMIBC) Incorporating the WHO 2004/2016 and WHO 1973 Classification Systems for Grade: An Update from the EAU NMIBC Guidelines Panel.欧洲泌尿外科学会（EAU）非肌肉浸润性膀胱癌（NMIBC）预后因素风险组，纳入世界卫生组织 2004/2016 年和世界卫生组织 1973 年分级系统：EAU NMIBC 指南小组的更新。
Eur Urol. 2021 Apr;79(4):480-488. doi: 10.1016/j.eururo.2020.12.033. Epub 2021 Jan 6.

引用本文的文献

1
Integrated spatial transcriptome and metabolism study reveals metabolic heterogeneity in human bladder cancer.整合空间转录组与代谢研究揭示人类膀胱癌中的代谢异质性。
Cancer Gene Ther. 2025 Aug 16. doi: 10.1038/s41417-025-00947-z.
2
Knockdown of CSF1R molecules enhances the antitumor effects of CD8 T lymphocytes in bladder cancer.敲低集落刺激因子1受体（CSF1R）分子可增强CD8 T淋巴细胞在膀胱癌中的抗肿瘤作用。
Discov Oncol. 2025 Jul 28;16(1):1426. doi: 10.1007/s12672-025-03244-1.
3
Computational Morphological Assessment of Bladder Cancer Tissue Is Prognostic of Recurrence and Overall Survival Following Transurethral Resection.膀胱癌组织的计算机形态学评估对经尿道切除术后的复发及总生存期具有预后价值。
JCO Clin Cancer Inform. 2025 Jul;9:e2400304. doi: 10.1200/CCI-24-00304. Epub 2025 Jul 22.
4
Impact of regular cystoscopy on prognosis in non-muscle-invasive bladder cancer: A nationwide study.定期膀胱镜检查对非肌层浸润性膀胱癌预后的影响：一项全国性研究。
Investig Clin Urol. 2025 Jul;66(4):302-310. doi: 10.4111/icu.20240362.
5
Expression of ALDH1 isotypes and its potential as a prognostic and diagnostic marker in patients with muscle invasive bladder cancer.醛脱氢酶1（ALDH1）亚型在肌层浸润性膀胱癌患者中的表达及其作为预后和诊断标志物的潜力。
Sci Rep. 2025 Jul 2;15(1):22599. doi: 10.1038/s41598-024-82460-1.
6
Key immune cells and their crosstalk in the tumor microenvironment of bladder cancer: insights for innovative therapies.膀胱癌肿瘤微环境中的关键免疫细胞及其相互作用：创新疗法的见解
Explor Target Antitumor Ther. 2025 Mar 31;6:1002304. doi: 10.37349/etat.2025.1002304. eCollection 2025.
7
Diagnostic Performance and Interobserver Agreement of the Vesical Imaging-Reporting and Data System (VI-RADS) in Bladder Cancer Staging: A Systematic Review.膀胱影像报告和数据系统（VI-RADS）在膀胱癌分期中的诊断性能及观察者间一致性：一项系统评价
Medicina (Kaunas). 2025 Mar 7;61(3):469. doi: 10.3390/medicina61030469.
8
Prognostic biomarker PSMD14 facilitates bladder cancer tumorigenesis and progression by regulating Nucleolin-YAP1 axis.预后生物标志物PSMD14通过调节核仁素-YAP1轴促进膀胱癌的发生和发展。
Transl Oncol. 2025 May;55:102370. doi: 10.1016/j.tranon.2025.102370. Epub 2025 Mar 22.
9
Optimal energy source selection strategies for en bloc resection in non-muscle invasive bladder cancer: a systematic review and network meta-analysis.非肌层浸润性膀胱癌整块切除的最佳能量源选择策略：一项系统评价和网状荟萃分析
World J Urol. 2025 Mar 10;43(1):155. doi: 10.1007/s00345-025-05513-8.
10
Comparison of neoadjuvant chemotherapy and combined chemotherapy with immunotherapy for muscle-invasive bladder cancer: a propensity score-matched analysis.新辅助化疗与免疫疗法联合化疗治疗肌层浸润性膀胱癌的比较：倾向评分匹配分析
Am J Transl Res. 2025 Jan 15;17(1):125-143. doi: 10.62347/IOZU2458. eCollection 2025.

本文引用的文献

1
Bladder cancer: Low adherence to guidelines in non-muscle-invasive disease.膀胱癌：非肌层浸润性疾病对指南的依从性较低。
Nat Rev Urol. 2016 Oct;13(10):570-1. doi: 10.1038/nrurol.2016.165. Epub 2016 Aug 31.
2
Systematic Review and Meta-Analysis on the Impact of Hexaminolevulinate- Versus White-Light Guided Transurethral Bladder Tumor Resection on Progression in Non-Muscle Invasive Bladder Cancer.关于六氨基乙酰丙酸与白光引导经尿道膀胱肿瘤切除术对非肌层浸润性膀胱癌进展影响的系统评价和荟萃分析
Bladder Cancer. 2016 Jul 27;2(3):293-300. doi: 10.3233/BLC-160060.
3
EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016.EAU 指南：非肌层浸润性膀胱尿路上皮癌：2016 年更新版。
Eur Urol. 2017 Mar;71(3):447-461. doi: 10.1016/j.eururo.2016.05.041. Epub 2016 Jun 17.
4
Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO Guideline.非肌肉浸润性膀胱癌的诊断与治疗：AUA/SUO 指南。
J Urol. 2016 Oct;196(4):1021-9. doi: 10.1016/j.juro.2016.06.049. Epub 2016 Jun 16.
5
The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part B: Prostate and Bladder Tumours.《2016 年世界卫生组织泌尿系统及男性生殖器官肿瘤分类-第 B 部分：前列腺和膀胱肿瘤》。
Eur Urol. 2016 Jul;70(1):106-119. doi: 10.1016/j.eururo.2016.02.028. Epub 2016 Mar 17.
6
Current Status of Urinary Biomarkers for Detection and Surveillance of Bladder Cancer.用于膀胱癌检测和监测的尿液生物标志物的现状
Urol Clin North Am. 2016 Feb;43(1):47-62. doi: 10.1016/j.ucl.2015.08.005.
7
EORTC Nomograms and Risk Groups for Predicting Recurrence, Progression, and Disease-specific and Overall Survival in Non-Muscle-invasive Stage Ta-T1 Urothelial Bladder Cancer Patients Treated with 1-3 Years of Maintenance Bacillus Calmette-Guérin.EORTC 列线图和风险分组用于预测非肌肉浸润性 Ta-T1 期尿路上皮膀胱癌患者接受 1-3 年卡介苗维持治疗后的复发、进展、疾病特异性和总生存情况。
Eur Urol. 2016 Jan;69(1):60-9. doi: 10.1016/j.eururo.2015.06.045. Epub 2015 Jul 23.
8
Systematic Review and Individual Patient Data Meta-analysis of Randomized Trials Comparing a Single Immediate Instillation of Chemotherapy After Transurethral Resection with Transurethral Resection Alone in Patients with Stage pTa-pT1 Urothelial Carcinoma of the Bladder: Which Patients Benefit from the Instillation?经尿道切除术后即刻单次灌注化疗与单纯经尿道切除治疗膀胱 pTa-pT1 期尿路上皮癌的随机对照试验的系统评价和个体患者数据分析：哪些患者从中获益？
Eur Urol. 2016 Feb;69(2):231-44. doi: 10.1016/j.eururo.2015.05.050. Epub 2015 Jun 16.
9
BCG-refractory vs. BCG-relapsing non-muscle-invasive bladder cancer: a prospective cohort outcomes study.卡介苗难治性与卡介苗复发性非肌层浸润性膀胱癌：一项前瞻性队列结局研究。
Urol Oncol. 2015 Mar;33(3):108.e1-4. doi: 10.1016/j.urolonc.2014.02.020.
10
[Clinical practice and adherence to the diagnosis and treatment of NMIBC guidelines: a report of a recognition based clinical cases study].[非肌层浸润性膀胱癌指南诊断与治疗的临床实践及依从性：一项基于认知的临床病例研究报告]
Urologia. 2015 Jan-Mar;82(1):58-70. doi: 10.5301/uro.5000107. Epub 2015 Mar 1.

指南之指南：非肌层浸润性膀胱癌

Guideline of guidelines: non-muscle-invasive bladder cancer.

作者信息

Woldu Solomon L, Bagrodia Aditya, Lotan Yair

机构信息

Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA.

出版信息

BJU Int. 2017 Mar;119(3):371-380. doi: 10.1111/bju.13760. Epub 2017 Jan 24.

DOI:10.1111/bju.13760
PMID:28058776
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5315602/
Abstract

Non-muscle-invasive bladder cancer (NMIBC) represents the vast majority of bladder cancer diagnoses, but this definition represents a spectrum of disease with a variable clinical course, notable for significant risk of recurrence and potential for progression. Management involves risk-adapted strategies of cystoscopic surveillance and intravesical therapy with the goal of bladder preservation when safe to do so. Multiple organizational guidelines exist to help practitioners manage this complicated disease process, but adherence to management principles among practising urologists is reportedly low. We review four major organizational guidelines on NMIBC: the American Urological Association (AUA)/Society of Urologic Oncology (SUO), European Association of Urology (EAU), National Comprehensive Cancer Network (NCCN), and National Institute for Health and Care Excellence (NICE) guidelines.

摘要

非肌层浸润性膀胱癌（NMIBC）占膀胱癌诊断病例的绝大多数，但这一定义涵盖了一系列临床病程各异的疾病，其显著特点是复发风险高且有进展的可能。治疗策略包括根据风险调整的膀胱镜监测和膀胱内灌注治疗，目的是在安全的情况下保留膀胱。现有多个组织制定的指南来帮助临床医生管理这一复杂的疾病过程，但据报道，执业泌尿科医生对管理原则的遵循程度较低。我们回顾了关于NMIBC的四项主要组织指南：美国泌尿外科学会（AUA）/泌尿肿瘤学会（SUO）、欧洲泌尿外科学会（EAU）、美国国立综合癌症网络（NCCN）以及英国国家卫生与临床优化研究所（NICE）指南。